Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

cancer ("NSCLC") are on track to initiate in the third quarter of 2010, the second half of 2010 and early 2011, respectively."

Recent Business Highlights:

OGX-011

    -   The European Medicines Agency confirmed that they are in overall
        agreement with our Phase III development plan for OGX-011 in patients
        with CRPC.
    -   Two peer-reviewed manuscripts were published that further explain the
        biological function of clusterin, its role in promoting tumor
        resistance to cancer treatment, and the role of an inhibitor of
        clusterin such as OGX-011, to enhance the effectiveness of cancer
        therapies. One of the co-authors to these manuscripts, Dr. Martin
        Gleave, is also the Company's Chief Scientific Advisor.

OGX-427

    -   Grant funding was secured for a randomized, investigator-sponsored
        Phase II trial of OGX-427 when administered as a monotherapy to
        patients with CRPC.
    -   Two peer-reviewed manuscripts were published that provide further
        insight into the mechanism of action of heat shock protein 27
        (Hsp27). OGX-427 is designed to reduce levels of Hsp27.
    -   Final results from a Phase 1 study involving OGX-427 will be
        presented as part of the Scientific Program in a General Poster
        Session with discussion at the ASCO 2010 Annual Meeting. These final
        data, including results combining OGX-427 with docetaxel, will update
        preliminary data that was featured in an oral presentation at the
        ASCO 2009 meeting.

Corporate Highlights

    -   Dr. Jack Goldstein and Ms. H. Stewart Parker were appointed to the
        board of directors. Dr. Goldstein joins the board as chairman. In
        addition, Dr. Martin Mattingly has agreed to stand for election at
        the Company's upcoming
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Pathwork Diagnostics, a,genomics-based diagnostics company focused on oncology, ... has initiated an,investigational study of the Pathwork(TM) Tissue ... to help determine a tumor,s origin so that,tissue-specific ... of the first,institutions in the country to evaluate ...
... Sensor for Airborne Biological Threats Receives Government ... ... 6 ICx Technologies, a developer of,advanced technology solutions for ... its AirSentinel(R) ambient aerosol,sensors for detection of airborne biological threats. ...
... Exchange Symbol: RVX, ORLANDO, FL, Nov. ... pleased to announce today key scientific data,was ... novel features of,RVX-208, at the American Heart ... of Compound RVX-208 Increases,Serum Levels of ApoA-I ...
Cached Biology Technology:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 2Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 3Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 4ICx Awarded Department of Defense Contract for AirSentinel Monitors 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 3
(Date:7/9/2014)... concern about the prevalence of antibiotic-resistant illness, Case ... pathway to disabling disease: blocking bacteria,s access to ... how bacterial siderophore, a small molecule, captures iron ... growth as well as how the body ... Their findings appear in a recent edition of ...
(Date:7/9/2014)... global census of Adlie penguins shows that the ... percent larger than previously estimated. Adlie penguins have ... monitor and understand the effects of climate change ... using high-resolution satellite imagery, researchers from Stony Brook ... new method that permits regular monitoring of Adlie ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
... Environmental and genetic factors influence a persons blood fat, ... disease (CAD). While there is some understanding of the ... defined. Now, in an international collaboration supported primarily by ... more than 25 genetic variants in 18 genes connected ...
... EVANSTON, Ill. --- Many researchers have tried to create a ... but most models have many different complicated factors, and no ... created a functional equation -- using only two parameters -- ... of Drosophila, better known as the fruit fly. They hope ...
... that facilitate the remarkably fast adaptation of intestinal bacteria ... issue of PLoS Genetics by researchers from INSERM and ... a simplified but ecologically relevant system the ... strain, Escherichia coli MG1655. E. coli is naturally resident ...
Cached Biology News:New genetic variants associated with lipid levels, risk for coronary artery disease 2New genetic variants associated with lipid levels, risk for coronary artery disease 3New genetic variants associated with lipid levels, risk for coronary artery disease 4New genetic variants associated with lipid levels, risk for coronary artery disease 5Researchers create mathematical model of fruit fly eyes 2Dissecting the genetic components of adaptation of E. coli to the mouse gut 2
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
... epitope specific for Nabeta2 is ... known proteins.,SPECIES REACTIVITIES: It ... human because the immunogen sequence ... Reactivity with other species has ...
Biology Products: